Justin Ryder

80 timestamped statements across 2 collections — auto-found in recorded discussions, each timestamp jumps to the exact moment.

Liver Tumors (Hepatoblastoma/HCC) · guest expert

Featured diaries

▶ Ep 15 · 1:25
The key takeaway is that the treatment should be offered to all children above the 85th percentile, and there should be no more watchful waiting.
quote · Liver Tumors (Hepatoblastoma/HCC)
▶ Ep 3 · 1:25
The key takeaway is that the treatment should be offered to all children above the 85th percentile, and there should be no more watchful waiting.
quote · Obesity
▶ Ep 15 · 0:37
The big picture view is that it's a multifactorial disease impacted by a robust gene-environment interaction.
quote · Liver Tumors (Hepatoblastoma/HCC)
▶ Ep 3 · 0:37
The big picture view is that it's a multifactorial disease impacted by a robust gene-environment interaction.
quote · Obesity

Nothing matches these filters — clear the search or widen the filters.

Liver Tumors (Hepatoblastoma/HCC) 40 entries

Pediatric Obesity Is a Disease: Treatment, Medications, Surgery & Equity in Care with Dr. Justin Ryder

▶ Ep 15 · 0:32
clinical Obesity is a disease impacted by behavior and represents a multifactorial disease impacted by a robust gene-environment interaction. ↗
▶ Ep 15 · 0:32
quote The data clearly supports that obesity is a disease impacted by behavior. ↗
▶ Ep 15 · 0:37
quote The big picture view is that it's a multifactorial disease impacted by a robust gene-environment interaction. ↗
▶ Ep 15 · 0:44
clinical Obesity is influenced by numerous factors including genetics, epigenetics, appetite and satiety hormone dysregulation, stress, economics, adverse life experiences, and environmental factors like calorically dense foods and sedentary lifestyles. ↗
▶ Ep 15 · 1:08
quote Historically, about 90% of our efforts over the past 50 years have been on prevention of childhood obesity. ↗
▶ Ep 15 · 1:08
epidemiological Historically, about 90% of efforts over the past 50 years have been on prevention of childhood obesity. ↗
▶ Ep 15 · 1:15
guideline The new AAP clinical practice guidelines clearly state that obesity is a disease. ↗
▶ Ep 15 · 1:22
quote They clearly state that obesity is a disease. ↗
▶ Ep 15 · 1:25
quote The key takeaway is that the treatment should be offered to all children above the 85th percentile, and there should be no more watchful waiting. ↗
▶ Ep 15 · 1:25
guideline Treatment should be offered to all children above the 85th percentile, and there should be no more watchful waiting. ↗
▶ Ep 15 · 1:41
guideline The guidelines describe a non-linear continuum of care starting with intensive health, behavior, and lifestyle treatment involving more than 26 contact hours over a 3 to 12-month period. ↗
▶ Ep 15 · 1:55
guideline Pharmacotherapy is FDA labeled for adolescents above the age of 12. ↗
▶ Ep 15 · 2:02
clinical Currently, there are 5 medications that are FDA approved for the treatment of adolescents with obesity. ↗
▶ Ep 15 · 2:08
guideline Bariatric surgery should be considered for those over the age of 13 years old with a BMI 1.2 times the 95th percentile. ↗
▶ Ep 15 · 2:29
clinical Wegovy, a GLP-1 receptor agonist, causes about 17% weight loss and is FDA approved in adolescents. ↗
▶ Ep 15 · 2:44
clinical Data in adults on tirzepatide shows significant change in body weight compared to placebo. ↗
▶ Ep 15 · 2:51
clinical Bariatric surgery studies show sustained weight loss in both adults and adolescent cohorts over several years. ↗
▶ Ep 15 · 2:51
clinical Oral GLP-1 medications are on the way in a few short years. ↗
▶ Ep 15 · 3:03
clinical There is no difference between Roux-en-Y gastric bypass and vertical sleeve gastrectomy in terms of percent BMI change from baseline over a 10-year period. ↗
▶ Ep 15 · 3:18
clinical There is significant heterogeneity in response to bariatric surgery, and weight regain is a significant problem. ↗
▶ Ep 15 · 3:24
clinical Bariatric surgery produces substantial improvements in conditions that commonly occur with obesity, like hypertension, diabetes, and high lipids. ↗
▶ Ep 15 · 3:40
clinical Weight regain is driven by a complex interplay between behaviors like physical activity and energy intake, and biological factors like energy expenditure and appetite and satiety hormones that regulate how full you feel. ↗
▶ Ep 15 · 3:56
clinical Weight regain factors are all influenced by genetics and the environment, including puberty, race, and socioeconomic status. ↗
▶ Ep 15 · 4:03
quote It is much easier to lose weight than to keep it off, which is demonstrated across many studies. ↗
▶ Ep 15 · 4:03
clinical It is much easier to lose weight than to keep it off, which is demonstrated across many studies. ↗
▶ Ep 15 · 4:22
epidemiological Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent pediatric liver disease. ↗
▶ Ep 15 · 4:31
clinical Obesity is a significant risk factor for MASLD. ↗
▶ Ep 15 · 4:34
epidemiological About 20% of youth in the United States have obesity, which is roughly 15 million children. ↗
▶ Ep 15 · 4:40
epidemiological Approximately 5 million children have both obesity and MASLD. ↗
▶ Ep 15 · 4:45
epidemiological Between 250,000 and 1 million children with obesity and MASLD will progress to cirrhosis and needing a liver transplant or having hepatocellular carcinoma. ↗
▶ Ep 15 · 4:56
epidemiological There are racial and ethnic differences in MASLD prevalence. ↗
▶ Ep 15 · 5:09
epidemiological Obesity affects at least 35% of adults and 20% of children in Illinois alone. ↗
▶ Ep 15 · 5:09
epidemiological The rates of severe forms of obesity are only increasing. ↗
▶ Ep 15 · 5:19
clinical Obesity significantly increases the risk of long-term health problems and early death. ↗
▶ Ep 15 · 5:23
epidemiological The economic impact of obesity is substantial, with reductions in GDP and increases in state spending. ↗
▶ Ep 15 · 5:30
quote Crucially, we need to reiterate that obesity is a disease driven by biology and that it is no one's fault. ↗
▶ Ep 15 · 5:30
opinion Obesity is a disease driven by biology and it is no one's fault. ↗
▶ Ep 15 · 5:37
opinion Access to effective obesity medications is a health equity issue. ↗
▶ Ep 15 · 5:41
epidemiological Obesity disproportionately affects people of color and those living in poverty. ↗
▶ Ep 15 · 5:49
clinical Organizations like the Stop Obesity Alliance are working to analyze how states are covering obesity medications in Medicaid programs, and there is significant variation across the country. ↗
Obesity 40 entries

Pediatric Obesity Is a Disease: Treatment, Medications, Surgery & Equity in Care with Dr. Justin Ryder

▶ Ep 3 · 0:32
quote The data clearly supports that obesity is a disease impacted by behavior. ↗
▶ Ep 3 · 0:32
clinical Obesity is a disease impacted by behavior and represents a multifactorial disease impacted by a robust gene-environment interaction. ↗
▶ Ep 3 · 0:37
quote The big picture view is that it's a multifactorial disease impacted by a robust gene-environment interaction. ↗
▶ Ep 3 · 0:44
clinical Obesity is influenced by numerous factors including genetics, epigenetics, appetite and satiety hormone dysregulation, stress, economics, adverse life experiences, and environmental factors like calorically dense foods and sedentary lifestyles. ↗
▶ Ep 3 · 1:08
epidemiological Historically, about 90% of efforts over the past 50 years have been on prevention of childhood obesity. ↗
▶ Ep 3 · 1:08
quote Historically, about 90% of our efforts over the past 50 years have been on prevention of childhood obesity. ↗
▶ Ep 3 · 1:15
guideline The new AAP clinical practice guidelines clearly state that obesity is a disease. ↗
▶ Ep 3 · 1:22
quote They clearly state that obesity is a disease. ↗
▶ Ep 3 · 1:25
quote The key takeaway is that the treatment should be offered to all children above the 85th percentile, and there should be no more watchful waiting. ↗
▶ Ep 3 · 1:25
guideline Treatment should be offered to all children above the 85th percentile, and there should be no more watchful waiting. ↗
▶ Ep 3 · 1:41
guideline The guidelines describe a non-linear continuum of care starting with intensive health, behavior, and lifestyle treatment involving more than 26 contact hours over a 3 to 12-month period. ↗
▶ Ep 3 · 1:55
guideline Pharmacotherapy is FDA labeled for adolescents above the age of 12. ↗
▶ Ep 3 · 2:02
clinical Currently, there are 5 medications that are FDA approved for the treatment of adolescents with obesity. ↗
▶ Ep 3 · 2:08
guideline Bariatric surgery should be considered for those over the age of 13 years old with a BMI 1.2 times the 95th percentile. ↗
▶ Ep 3 · 2:29
clinical Wegovy, a GLP-1 receptor agonist, causes about 17% weight loss and is FDA approved in adolescents. ↗
▶ Ep 3 · 2:44
clinical Data in adults on tirzepatide shows significant change in body weight compared to placebo. ↗
▶ Ep 3 · 2:51
clinical Oral GLP-1 medications are on the way in a few short years. ↗
▶ Ep 3 · 2:51
clinical Bariatric surgery studies show sustained weight loss in both adults and adolescent cohorts over several years. ↗
▶ Ep 3 · 3:03
clinical There is no difference between Roux-en-Y gastric bypass and vertical sleeve gastrectomy in terms of percent BMI change from baseline over a 10-year period. ↗
▶ Ep 3 · 3:18
clinical There is significant heterogeneity in response to bariatric surgery, and weight regain is a significant problem. ↗
▶ Ep 3 · 3:24
clinical Bariatric surgery produces substantial improvements in conditions that commonly occur with obesity, like hypertension, diabetes, and high lipids. ↗
▶ Ep 3 · 3:40
clinical Weight regain is driven by a complex interplay between behaviors like physical activity and energy intake, and biological factors like energy expenditure and appetite and satiety hormones that regulate how full you feel. ↗
▶ Ep 3 · 3:56
clinical Weight regain factors are all influenced by genetics and the environment, including puberty, race, and socioeconomic status. ↗
▶ Ep 3 · 4:03
quote It is much easier to lose weight than to keep it off, which is demonstrated across many studies. ↗
▶ Ep 3 · 4:03
clinical It is much easier to lose weight than to keep it off, which is demonstrated across many studies. ↗
▶ Ep 3 · 4:22
epidemiological Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent pediatric liver disease. ↗
▶ Ep 3 · 4:31
clinical Obesity is a significant risk factor for MASLD. ↗
▶ Ep 3 · 4:34
epidemiological About 20% of youth in the United States have obesity, which is roughly 15 million children. ↗
▶ Ep 3 · 4:40
epidemiological Approximately 5 million children have both obesity and MASLD. ↗
▶ Ep 3 · 4:45
epidemiological Between 250,000 and 1 million children with obesity and MASLD will progress to cirrhosis and needing a liver transplant or having hepatocellular carcinoma. ↗
▶ Ep 3 · 4:56
epidemiological There are racial and ethnic differences in MASLD prevalence. ↗
▶ Ep 3 · 5:09
epidemiological Obesity affects at least 35% of adults and 20% of children in Illinois alone. ↗
▶ Ep 3 · 5:09
epidemiological The rates of severe forms of obesity are only increasing. ↗
▶ Ep 3 · 5:19
clinical Obesity significantly increases the risk of long-term health problems and early death. ↗
▶ Ep 3 · 5:23
epidemiological The economic impact of obesity is substantial, with reductions in GDP and increases in state spending. ↗
▶ Ep 3 · 5:30
quote Crucially, we need to reiterate that obesity is a disease driven by biology and that it is no one's fault. ↗
▶ Ep 3 · 5:30
opinion Obesity is a disease driven by biology and it is no one's fault. ↗
▶ Ep 3 · 5:37
opinion Access to effective obesity medications is a health equity issue. ↗
▶ Ep 3 · 5:41
epidemiological Obesity disproportionately affects people of color and those living in poverty. ↗
▶ Ep 3 · 5:49
clinical Organizations like the Stop Obesity Alliance are working to analyze how states are covering obesity medications in Medicaid programs, and there is significant variation across the country. ↗